|
|
|
|
|
|
|
|
|
Updated: 11/3/2006 11:46:06 AM
|
|
|
Elizabeth Barry, Research Assistant Professor of Community and Family Medicine (Photo courtesy of Barry)Dartmouth researchers are among a team of doctors that have learned more about how people may or may not benefit from taking aspirin in the effort to curb colon cancer. Their study, which appears in the Oct. 18 issue of the Journal of the National Cancer Institute, finds that the beneficial effect of aspirin may be limited to individuals who have a specific genetic variation in their ODC gene.
"There is evidence that aspirin and related anti-inflammatory drugs can reduce the risk of colorectal adenomas [polyps] and cancer," says Elizabeth Barry, a research assistant professor of community and family medicine at Dartmouth Medical School, and one the authors of the study. "And with this study, we looked closer at the impact of aspirin in people who have a higher risk of developing colorectal adenomas, which lead to cancer, by examining their ODC genotype. So now we know that aspirin appears to work better in people who have this slight genetic variation, and this finding could potentially be clinically useful in the future by allowing physicians to predict which individuals are likely to benefit from aspirin use for colorectal cancer chemoprevention."
The researchers studied 973 subjects over three years as part of the Aspirin/Folate Polyp Prevention Study. In a randomized manner, some were given aspirin and some were given placebos. Almost half of the participants carried one or two copies of the ODC genetic variation. The study found that there was no association between carrying the genetic variation and the occurrence or new adenomas, but the genotype did influence the effect of aspirin on adenoma development. Those with the ODC genetic variation were 23 percent less likely to develop new adenomas and 49 percent less likely to develop more advanced lesions, which also lead to cancer.
Other authors on the paper include John A. Baron and Maria V. Grau, with Dartmouth Medical School; Shubha Bhat and Thomas G. O'Brien, with the Institute for Medical Research in Wynnewood, Penn.; Carol A. Burke, with the Cleveland Clinic Foundation; Robert S. Sandler, with the University of North Carolina; Dennis J. Ahnen, with the University of Colorado Health Sciences Center in Denver; and Robert W. Haile, with the University of Southern California, Los Angeles.
© 2006 HealthNewsDigest.com
|
|
|
|
|
|
|
|
The materials and articles published on DentalPlans.com
are for informational purposes only. Although DentalPlans.com strives to be accurate
and complete, the information is provided without liability for errors. DentalPlans.com
does not warrant the accuracy or completeness of the information, text graphics,
links, or other items contained on DentalPlans.com.
DentalPlans.com expressly disclaims liability for
errors or omissions in these materials and DentalPlans.com makes no commitment to
update the information on DentalPlans.com.
DentalPlans.com expressly disclaims all liability
for the use or interpretation by others of information on DentalPlans.com. Decisions
based on information contained on DentalPlans.com are the sole responsibility of
the visitors, and visitors agree to hold DentalPlans.com and its Affiliates harmless
against any claims for damages arising from decisions visitors make on such information.
Nothing on DentalPlans.com constitutes medical advice
or other forms of advice. DentalPlans.com assumes no responsibility for material
created or published by third parties linked to DentalPlans.com with or without
DentalPlans.com’s knowledge.
|
|
